Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. (Q54594692)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

0 references

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

author name string

Phyllis R Wachsberger

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Richard Yaacov Lawrence

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Yi Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Xu Xia

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Barbara Andersen

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

publication date

23 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

105

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

181-190

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

https://scigraph.springernature.com/pub.10.1007/s11060-011-0580-y

0 references

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Genetic and hypoxic regulation of angiogenesis in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Advances in the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Stress and radiation-induced activation of multiple intracellular signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

EGFRvIII-mediated radioresistance through a strong cytoprotective response.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

X-RAY AND ULTRAVIOLET SENSITIVITY OF SYNCHRONIZED CHINESE HAMSTER CELLS AT VARIOUS STAGES OF THE CELL CYCLE.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0580-Y

21 January 2018

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/21516367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-011-0580-Y

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21516367

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54594692&oldid=1409130909"